CAR-T Cell Therapy Market

CAR-T Cell Therapy Market - (Target Type: CD19, BCMA, HER2, GD2, CD20, Mesothelin, CD33, Others; Application: Diffuse large B-cell lymphoma, Chronic lymphocytic leukemia, Multiple myeloma, Acute lymphoblastic leukemia, and Others) – Global Opportunity Analysis, and Market Forecast, 2018–2028

A prominent research firm, Cognizance Market Research added a cutting-edge industry report on the “Global CAR-T Cell Therapy Market”. The report studies the current as well as past growth trends and opportunities for the market to gain valuable insights during the forecast period from 2020 to 2028.

Global CAR-T Cell Therapy Market Analysis

According to cognizance market research the Global CAR-T Cell Therapy Market was valued at USD 360.5 Million in 2019 and expected to grow at a CAGR of 35.1% from 2020 to 2028.

What is Global CAR-T Cell Therapy?

Chimeric antigen receptor therapy or CAR-T cell therapy is a novel form of immunotherapy that uses specifically modified T cells to more precisely target melanoma cells. In recent years, for cancer care, selective immunotherapies containing CAR-T cell therapies have been preferred over chemotherapy, surgery, and radiation. the therapy helps to strengthen the immune system against tumors and target the cancer cells of the patient.

CAR-T Cell Therapy MarketGlobal CAR-T Cell Therapy Market Outlook

In this report, the market outlook segment mainly includes important dynamics of the market which include drivers, restraints, opportunities, and challenges tackled by the industry. Opportunities and challenges are extrinsic factors whereas, drivers and restraints are intrinsic factors of the market.

In CAR-T therapy, patients’ blood-derived T cells are further changed in the clinical laboratory by adding special protein receptors to the T cells which attack cancer cells. The special receptor is recognized as CAR that is a Chimeric Antigen Receptor that binds to a particular protein on cancer cells of the patient. One revolutionary technique for programming the immune system to combat cancer is CAR T-cell therapy. Currently, the FDA has approved CAR-T therapy to treat some forms of cancer, including refractory non-Hodgkin lymphoma and pediatric recurrent acute lymphoblastic leukemia. The growing prevalence of cancer and a growing number of patients presenting response failure to substitute treatments are anticipated to foster the growth CAR-T cell therapy market globally.

Report Overview:

The report offers the revenue of this market for the period 2018–2028, considering 2018 as a historical year, 2019 as the base year, and 2020 to 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the Global CAR-T Cell Therapy market for the forecast period. This market report provides insights and in-depth analysis into developments impacting enterprises and businesses on a regional and global level. The report covers the Global CAR-T Cell Therapy market performance in terms of revenue contribution from several segments and comprises a detailed analysis of key drivers, trends, restraints, and opportunities prompting revenue growth of the Global CAR-T Cell Therapy market.

The report has been prepared after wide-ranging secondary and primary research. Secondary research included internet sources, numerical data from government organizations, trade associations, and websites. Analysts have also employed an amalgamation of bottom-up and top-down approaches to study numerous phenomena in the global CAR-T Cell Therapy market. Secondary research involved a detailed analysis of significant players’ Type portfolio. Literature review, press releases, annual reports, white paper, and relevant documents have been also studied to understand the global CAR-T Cell Therapy market. Primary research involved a great extent of research efforts, wherein experts carried out interviews telephonic as well as questioner-based with industry experts and opinion-makers.

The report includes an executive summary, along with a growth pattern of different segmented included in the scope of the study. The Y-o-Y analysis with elaborate market insights has been provided in the report to comprehend the Y-o-Y trends in the Global CAR-T Cell Therapy market. Additionally, the report focuses on altering competitive dynamics in the global market. These indices serve as valued tools for present market players as well as for companies interested in participating in the Global CAR-T Cell Therapy market. The subsequent section of the Global CAR-T Cell Therapy report highlights the USPs, which include key industry events (Type launch, research partnership, acquisition, etc.), technology advancements, pipeline analysis, prevalence data, and regulatory scenario.

Global CAR-T Cell Therapy Market Competitive Landscape

The “Global CAR-T Cell Therapy Market” study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Novartis, Agios Pharmaceutical, Juno Therapeutics, Atara Biotherapeutics, China Immunotech Co., Ltd., Shenzhen BinDeBio Ltd., Autolus Limited, Kite Pharma, bluebird bio, Calibr, Carina Biotech, Bellicum Pharmaceuticals, CARsgen Therapeutics, Celgene Corporation, Cellectis, Allogene Therapeutics, Cell Medica, AbbVie,  Amgen, Cell Design Labs, Celyad, Celularity, Fate Therapeutics, Gilead Sciences, Fortress Bio, Sorrento Therapeutics, Inc., JW Therapeutics, Medisix Therapeutics, Ziopharm, Janssen Biotech, Mustang Bio, Nanjing Legend Biotech, Precision Biosciences, and Posedia Therapeutics. Company overview (company description, Type portfolio, geographic presence, employee strength, Key management, etc.), financials, recent developments, and key strategies are some of the features of companies profiled in this market report.

Key Questions Answered in Global CAR-T Cell Therapy Market Report

  • What are the major players operating in this market?
  • What are trends, drivers, opportunities, and challenges in this market?
  • Which is the leading country in this market?
  • What are the revenue share forecasts of key sections of the Global CAR-T Cell Therapy during the estimated timeframe?
  • Which segment is expected to lead this market in terms of revenue by 2028?
  • How partnerships & alliances among companies operating in the market are broadening the scope of this market?
  • Who are the top 5 leaders of this market?
  • Which unmet needs will remain unaddressed over the projected period?

The Global CAR-T Cell Therapy Market has been segmented as below:

Global Market, by Target Type

  • CD19
  • BCMA
  • HER2
  • GD2
  • CD20
  • Mesothelin
  • CD33
  • Other (EBV, etc.)

Global Market, by Application

  • Diffuse large B-cell lymphoma
  • Chronic lymphocytic leukemia
  • Multiple myeloma
  • Acute lymphoblastic leukemia
  • Others

Global Market, by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

"All Field Required" indicates required fields

NameAll Field Required
AddressAll Field Required

"All Field Required" indicates required fields

NameAll Field Required
AddressAll Field Required


A Global Pandemic

Request the coronavirus impact analysis across industries and markets

This website uses cookies and asks your personal data to enhance your browsing experience.